Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2014
09/25/2014WO2014150651A1 Racecadotril liquid compositions
09/25/2014WO2014150639A1 Process for preparing beta 3 agonists and intermediates
09/25/2014WO2014150609A1 Metadichol r liquid and gel nanoparticle formulations
09/25/2014WO2014150596A1 Compositions for treating skin disorders
09/25/2014WO2014150571A1 Reducing proinflammatory response
09/25/2014WO2014150512A1 Method and products for treating diabetes
09/25/2014WO2014150451A1 Antimicrobial polyamide compositions and mastitis treatment
09/25/2014WO2014150395A1 Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
09/25/2014WO2014150351A1 Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women
09/25/2014WO2014150344A1 C2-azaspiro iminothiazine dioxides as bace inhibitors
09/25/2014WO2014150340A1 S-imino-s-oxo iminothiadiazine compounds as bace inhibitors, compositions, and their use
09/25/2014WO2014150338A1 Amine functional polyamides
09/25/2014WO2014150331A1 S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
09/25/2014WO2014150326A1 Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
09/25/2014WO2014150318A1 Therapeutic agent for enhancing mitochondrial function
09/25/2014WO2014150289A1 Compounds and uses thereof for the modulation of hemoglobin
09/25/2014WO2014150276A1 Compounds and uses thereof for the modulation of hemoglobin
09/25/2014WO2014150268A1 Compounds and uses thereof for the modulation of hemoglobin
09/25/2014WO2014150261A1 Compounds and uses thereof for the modulaton of hemoglobin
09/25/2014WO2014150258A1 Compounds and uses thereof for the modulation of hemoglobin
09/25/2014WO2014150256A1 Compositions and methods for the modulation of hemoglobin (s)
09/25/2014WO2014150252A1 Methods of treatment associated with the granulocyte colony-stimulating factor receptor
09/25/2014WO2014150203A1 Salts of treprostinil
09/25/2014WO2014150174A1 Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells
09/25/2014WO2014150139A1 Activated soy pod fiber
09/25/2014WO2014150132A1 Inhibitors of the renal outer medullary potassium channel
09/25/2014WO2014150114A1 Substituted pyridizinone derivatives as pde10 inhibitors
09/25/2014WO2014150074A1 Compositions and methods for nucleic acid delivery
09/25/2014WO2014150067A1 Concentrated aqueous azalide formulations
09/25/2014WO2014150043A1 Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
09/25/2014WO2014149998A1 Systemic administration of androgen in treating dry eye syndrome
09/25/2014WO2014149987A1 Bicyclic pyrrole derivatives useful as agonists of gpr120
09/25/2014WO2014149973A2 Compositions and methods for treating bone diseases
09/25/2014WO2014149939A1 Dye free liquid therapeutic solution
09/25/2014WO2014149848A1 Tetrandrine family pharmaceutical formulations and method
09/25/2014WO2014149837A1 Compounds and methods to enhance the oral availability of glycomimetics
09/25/2014WO2014149819A1 Bicyclic analgesic compounds
09/25/2014WO2014149789A1 Combination of canagliflozin and probenecid for the treament of hyperuricemia
09/25/2014WO2014149719A1 Multi-layer cosmetic films
09/25/2014WO2014149529A1 Coated phenylephrine particles and use thereof in pharmaceutical formulations
09/25/2014WO2014149526A1 Phenylephrine resinate particles
09/25/2014WO2014149525A1 Phenylephrine resinate particles and use thereof in pharmaceutical formulations
09/25/2014WO2014149494A1 Sanguinarine analog pp2c inhibitors for cancer treatment
09/25/2014WO2014149397A1 Compositions comprising an opioid and an additional active pharmaceutical ingredient for rapid onset and extended duration of analgesia that may be administered without regard to food
09/25/2014WO2014149280A1 Treatment of pets with sirtuin activators
09/25/2014WO2014149171A1 Total synthesis of thaxtomin a analogues and their intermediates
09/25/2014WO2014149164A1 Mk2 inhibitors and uses thereof
09/25/2014WO2014149160A1 Polyalkoxylated alcohols as excipients for pharmaceutical compositions
09/25/2014WO2014149069A1 Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
09/25/2014WO2014148951A1 Novel therapeutic mirtazapine combinations for use in pain disorders
09/25/2014WO2014148949A1 Alkyl 2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2н-pyrimidin-1-yl)-3-hydroxy- tetrahydro-furan-2-yl-methoxy]-phenoxy-phosphoryl-amino}-propionates, nucleoside inhibitors of hcv ns5b rna-polymerase, and methods for producing and use thereof
09/25/2014WO2014148911A1 Fermented nutrition with non-digestible oligosaccharides with increased iron bioavailability
09/25/2014WO2014148910A1 Fermented nutrition high in lactose with increased iron bioavailability
09/25/2014WO2014148887A1 Fermented nutrition with non-digestible oligosaccharides with increased iron bioavailability
09/25/2014WO2014148886A1 Fermented nutrition high in lactose with increased iron bioavailability
09/25/2014WO2014148765A1 Dental nanofiber chip equipped with medication and method for manufacturing same
09/25/2014WO2014148718A1 Bone morphogenetic compound and application thereof
09/25/2014WO2014148638A1 Aptamer to il-17 and use thereof
09/25/2014WO2014148620A1 Double-stranded nucleic acid binder, said binder—double-stranded nucleic acid complex, pharmaceutical composition containing said complex, and production method for said complex
09/25/2014WO2014148574A1 Inhibition of production of il-2
09/25/2014WO2014148529A1 Double-stranded nucleic acid molecule, dna, vector, cancer cell proliferation inhibitor, and pharmaceutical product
09/25/2014WO2014148520A1 Solid preparation
09/25/2014WO2014148455A1 Terpenoid derivative
09/25/2014WO2014148451A1 Fused heterocyclic compound or salt thereof, pesticide for agricultural and horticultural use containing said compound, and usage method therefor
09/25/2014WO2014148450A1 Two-layer separation-type eye drop containing squalane
09/25/2014WO2014148438A1 Therapeutic agent for hepatitis c which comprises 4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzene derivative
09/25/2014WO2014148422A1 Licorice hydrolysis extraction composition
09/25/2014WO2014148216A1 Pharmaceutical composition for treatment of inflammatory bowel disease
09/25/2014WO2014148136A1 Compound having anti-allergic activity and use of same
09/25/2014WO2014148053A1 Use of ep4 receptor antagonists in the treatment of cartilage disease
09/25/2014WO2014147638A1 A multifunctional natural wound healing matrix
09/25/2014WO2014147636A1 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
09/25/2014WO2014147631A1 Formulation comprising gefitinib as oral suspension
09/25/2014WO2014147611A1 Quinolines derivatives as novel anticancer agents
09/25/2014WO2014147610A1 Astaxanthin anti-inflammatory synergistic combinations
09/25/2014WO2014147597A1 Aminofucoidan as a vector for fibrinolysis in thrombotic diseases
09/25/2014WO2014147586A1 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
09/25/2014WO2014147581A1 Plant extracts of ptaeroxylon obliquum and compounds having antimicrobial and antihelminthic activity
09/25/2014WO2014147578A2 Antibacterial compounds against drug resistant bacteria
09/25/2014WO2014147567A1 Pharmaceutical compositions comprising everolimus
09/25/2014WO2014147559A1 Cd7 receptor aptamers
09/25/2014WO2014147526A1 Tofacitinib oral sustained release dosage forms
09/25/2014WO2014147405A1 Combination comprising zidovudine and polymyxin
09/25/2014WO2014147377A1 An oral dosage form having an outer surface comprising a medicated print
09/25/2014WO2014147353A1 Use of 4-{3-[cis-hexahydrocyclopenta[c]pyrrole-2(1h)-yl]propoxy}benzamide for treating neuropathic pain
09/25/2014WO2014147287A1 Nanocrystalline cellulose (ncc) as an antiviral compound
09/25/2014WO2014147246A1 Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
09/25/2014WO2014147242A1 Piperaquine microcapsules and compositions containing them
09/25/2014WO2014147214A1 Use of sedoheptulose for prevention or treatment of inflammation
09/25/2014WO2014147213A1 Use of sedoheptulose as a nutritional supplement
09/25/2014WO2014147204A1 Heteroaryl substituted indazoles
09/25/2014WO2014147203A1 3-heteroaryl substituted indazoles
09/25/2014WO2014147178A1 Hdac6 inhibitors and uses thereof
09/25/2014WO2014147144A1 Diaminoheteroaryl substituted indazoles
09/25/2014WO2014147119A1 Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash)
09/25/2014WO2014147112A1 Antioxidatively active composition and the use thereof
09/25/2014WO2014147096A1 Pharmaceutical compositions comprising an active agent
09/25/2014WO2014147095A1 Lipohillic oligonucleotide analogs
09/25/2014WO2014147016A1 Ror gamma modulators
09/25/2014WO2014146975A1 FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca)
1 ... 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 ... 7860